超訊通信(603322.SH):前期與濟寧寧華合同在正常履約中,且交付了1.23億相關設備產品已經驗收通過
格隆匯8月16日丨超訊通信(603322.SH)在投資者互動平台表示,本次訴訟案件,公司與子公司並非浪潮的合同相對方且無直接業務往來,公司及子公司與客户濟寧寧華業務合作上不存在法律糾紛,浪潮不起訴其供應商轉而起訴間接供應商行為也不符合一般訴訟邏輯。公司前期與濟寧寧華合同在正常履約中,且交付了1.23億相關設備產品已經驗收通過。有關後續進展情況,公司將嚴格按照相關規定及時履行信息披露義務,敬請留意公司披露的公吿。本次訴訟不會影響公司正常經營,公司在相應領域的市場和技術,將一如既往地開展,按照既定目標完成任務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.